INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 196 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $767,000 | -26.6% | 16,000 | -3.6% | 0.06% | -39.3% |
| Q1 2020 | $1,045,000 | -31.9% | 16,600 | +34.0% | 0.11% | 0.0% |
| Q4 2019 | $1,535,000 | +312.6% | 12,390 | +121.2% | 0.11% | +296.3% |
| Q3 2019 | $372,000 | -62.9% | 5,600 | -55.6% | 0.03% | -62.0% |
| Q2 2019 | $1,003,000 | -33.1% | 12,600 | -6.0% | 0.07% | -34.9% |
| Q1 2019 | $1,499,000 | +11.0% | 13,400 | 0.0% | 0.11% | -12.1% |
| Q4 2018 | $1,351,000 | -10.9% | 13,400 | +11.7% | 0.12% | +7.8% |
| Q3 2018 | $1,516,000 | +100.8% | 12,000 | +33.3% | 0.12% | +94.9% |
| Q2 2018 | $755,000 | – | 9,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |